Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Melissa J. Karau, Suzannah M. Schmidt-Malan, Qun Yan, Kerryl E. Greenwood-Quaintance, Jayawant Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

Original languageEnglish (US)
Article numbere01235-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number10
DOIs
StatePublished - 2019

Keywords

  • CF-301
  • Daptomycin
  • Exebacase
  • Methicillin-resistant Staphylococcus aureus
  • Osteomyelitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats'. Together they form a unique fingerprint.

  • Cite this